A. Guarini et al., Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission, BR J HAEM, 113(1), 2001, pp. 136-142
The role of the host immune compartment in the control of chronic myeloid l
eukaemia (CML) has been suggested by numerous biological and clinical evide
nce. In the present study, the phenotypic and functional machinery of both
T and cytotoxic lymphocytes was evaluated in a series of CML patients in co
mplete haematological, and frequently also in cytogenetic, remission after
treatment with interferon (IFN) alpha or hydroxyurea, and compared with the
profile observed in patients at diagnosis and in normal controls. in parti
cular, the lymphocyte subset distribution, the cytotoxic activity and the i
ntracellular production of tumour necrosis factor (TNF)alpha and IFN gamma
by CD4(+), CD8(+) and CD56(+) cells were investigated, CML patients in comp
lete haematological remission showed a normalized CD4/CD8 T-cell subset dis
tribution, as well as a restored spontaneous and interleukin 2 (IL-2) induc
ed cytotoxic function compared with the pattern observed at diagnosis, This
was associated with a significantly increased proportion of activated CD4(
+) lymphocytes (CD25(+)). TNF alpha and IFN gamma production by CD4(+), CD8
(+) and CD56(+) lymphocytes was significantly enhanced compared with that o
f patients at diagnosis. However, the values were lower than those of norma
l controls. These results indicate that, in contrast to the observations at
presentation, CML patients, at the time of the best possible response to t
reatment, show a normalized T-cell subset distribution associated with an a
ctivated CD4 T-cell compartment and a restored cytotoxic activity, In addit
ion, they also show a markedly increased intracellular cytokine production
by the lymphoid populations that play an important role in the process of s
pecific tumour recognition. The design of therapeutic strategies aimed at s
timulating the host immune compartment finds a further rationale for CML, p
atients responsive to treatment with both IFN alpha and hydroxyurea.